Healthcare group Chiesi is investing €350m to bring the new formulations to market by 2025, expected to reduce the carbon footprint of pressurised metered-dose inhalers by 90%.

Reserachers suggest switching to alternative, ‘greener’ inhalers would result in large carbon savings